The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past
decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6 …

Because of the increasing use of immunosuppressive and biological drugs, the occurrence
of opportunistic infections has become a key safety issue for patients with inflammatory …

6.1. Background The incidence of tuberculosis (TB) is a concern at the start of the third
millennium, particularly with the increase of multiresistant (MDR-TB) and extended resistant …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

BACKGROUND & AIMS: We sought to identify and quantify the clinical factors that were
associated with opportunistic infections in inflammatory bowel disease patients. METHODS …

Background & Aims The risk of infection associated with tumor necrosis factor antagonists
(anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of …

The use of biological agents and immunomodulators for inflammatory bowel disease (IBD)
has remarkably improved disease management in the current era but at the same time has …

OBJECTIVES: Several anti-tumor necrosis factor-α (TNFα) antibodies have demonstrated
efficacy in Crohn's disease (CD) and ulcerative colitis (UC). These drugs carry the …

Background & Aims Safety issues are a major concern for patients considering treatments
for inflammatory bowel disease (IBD). We performed a systematic review and meta-analysis …

Background There remain concerns about the safety of infliximab therapy in patients with
inflammatory bowel disease (IBD). Aim To assess the association between the initiation of …